KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young‐Joo Jin, Seung‐seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim
Abstract
What is the diagnostic and prognostic performance of NITs for portal hypertension?10.What is the performance of NITs for predicting hepatocellular carcinoma (HCC), hepatic decompensation, and death?11.How useful are NITs for monitoring the progression of CLDs? 12. What is the usefulness of NITs for evaluating liver fibrosis in pediatric and adolescent patients?Internal and external review and approval process Manuscripts and recommendations prepared by each member were reviewed for content integrity and validity of evidence through several committee meetings, and the quality of the guidelines was evaluated according to the Appraisal of Guidelines for Research and Evaluation II (AGREE II) criteria.The recommendations were assessed and revised based on critical review by the Delphi Committee, which was composed of 11 experts in the field of hepatology belonging to the KASL.The guidelines were reviewed at a meeting of an external review board consisting of six specialists in the field of hepatology and at a symposium open to all KASL members and the public, and they were then further modified.